text_combined: sterling stock watch smallcap biotech report stem cell cryogenics stem cell investing emerging biotech stocks company spotlight bio matrix scientific group inc driving 75 billion dollar year biotechnology medical device industries demand new products improve patient safety decrease healthcare cost importantly enhance human life symbol bmxp trading price 0 94 bio matrix scientific group inc bio matrix scientific group inc san diego based development stage company business medical devices monitoring systems research development commercialization bio matrix scientific group inc aligning partners offer key technologies biomedical device development tissue engineering cell culturing genome therapy drug delivery systems polymer coating medical devices ensure cell transference done minimal damage cells lead better yields stem cell extraction along better outcomes patients tissue management procedures recent news spokesperson company said board directors plans spin 6 035 501 shares common stock frezer inc wholly owned subsidiary bio matrix scientific group bmxp shareholders record may 31 2005 represents one share frezer inc every one share bio matrix scientific group inc pink sheets bmxp owned post reverse split ground floor company enters production phase bio matrix scientific group inc announced collective technologies manufacture bio matrix first set stem cell devices company anticipates set instruments sometime within next two weeks bmxp also recently finalized applications 3 new devices first step towards full production devices first set devices used 510 k testing trade shows presentations physicians researchers collective technologies enables us manufacture products efficient cost effective way possible noted brian pockett managing director coo bio matrix scientific impressed collective technologies quality record responsiveness flexibility critical production objectives bio matrix sees event nearing point company green lights full production stem cell tissue management instruments real deal management philip watts ph company director research development highly recognized field james l lambert ph bio instrument scientific advisor dr lambert specializes development next generation bio instrumentation use medical research dr lambert jet propulsion laboratory 17 years last five years served technical group supervisor intelligent instrument systems technology group dr lambert leads multidisciplinary group whose members advanced degrees chemistry biology electrical engineering computer science charter group develop advanced situ instruments sensors nasa agencies geoffrey neill ph president company dr neill recently served director stem cell laboratories scientific research cryo cell international inc otc ccel cryo cell international represents world largest u cord stem cell banking firm appointment dr neill president bio matrix scientific group inc signals company aggressive growth plans stem cell research devices biomedical devices continued growth development stem cell cryogenic banks said brian pockett managing director coo bio matrix scientific product development stem cell cryogenics instrumentation stem cell research tissue management non invasive bio systems monitoring measuring devices niche medical device instrumentation company recently filed provisional patent application u patent office anticipates numerous utility patents result filing investment prosective bio matrix four pronged revenue strategy different trajectory different inflection points company spreading risk different operating segments varying investment requirement levels risk larger companies medical device industry aggressive smaller companies always takeover targets potential bmxp market size segments chosen operate huge tissue management instruments market size alone 860 million provisional patent application already filed pipeline important disclaimer information within email contains forward looking statements within meaning section 27 securities act 1933 section 21 b securities exchange act 1934 statements express involve discussions respect predictions goals expectations beliefs plans projections objectives assumptions future events performance statements historical fact may forward looking statements forward looking statements based expectations estimates projections time statements made involve number risks uncertainties could cause actual results events differ materially presently anticipated forward looking statements action may identified use words projects foresee expects estimates believes understands anticipates statements indicating certain actions may could might occur information provided within email pertaining investing stocks securities must understood information provided investment advice emerging equity alert advises readers subscribers seek advice registered professional securities representative deciding trade stocks featured within email none material within report shall construed kind investment advice compliance section 1 compensated thirty thousand dollars dissemination profile aware inherent conflict interest resulting holdings due intent profit liquidation shares shares may sold time even positive statements made regarding company